Selected synthetic case / actual retained answers
When a diagnostic clue becomes too specific
Both tools recognise Quebec platelet disorder and the genetic-panel gap. The difference is how confidently a platelet aggregation finding is allowed to identify the disease.
A selected synthetic development case, published by MontMedical. The clinical fingerprints match, but the exact prompts submitted to OpenEvidence were not independently retained. This is an editorial comparison of historical answers, not a blinded efficacy trial.
Our editorial assessment
How the retained answers rate.
OpenEvidence8.1/10
MontMedical8.4/10
MontMedical has the better-calibrated diagnostic wording.
Same five criteria and weights for both systems| Criterion and weight | OpenEvidence | MontMedical |
|---|
| Diagnosis and case fit 25% | 9/10 | 9/10 |
|---|
| Interpretation of tests and experiments 25% | 9/10 | 9/10 |
|---|
| Strength of the claims 20% | 6/10 | 8/10 |
|---|
| Decisions and next steps 15% | 8/10 | 7/10 |
|---|
| Clarity and teaching 15% | 8/10 | 8/10 |
|---|
Why each criterion received its mark
Diagnosis and case fit
OpenEvidence · 9/10: Correctly identifies QPD and the delayed familial bleeding pattern.
MontMedical · 9/10: Correct leading diagnosis linked to delayed bleeding and the family pattern.
Interpretation of tests and experiments
OpenEvidence · 9/10: Explains platelet-localised lysis and the unassessed PLAU copy-number alteration well.
MontMedical · 9/10: Preserves the plasma-versus-platelet distinction and the structural-variant coverage gap.
Strength of the claims
OpenEvidence · 6/10: Calls the epinephrine finding specific and recommends removing the VWD label more firmly than the case establishes.
MontMedical · 8/10: Uses provisional wording and avoids the specific-clue claim; it still compresses what the VWF observations can exclude.
Decisions and next steps
OpenEvidence · 8/10: Gives targeted testing and makes bleeding management explicit; categorical record-label removal is a weakness.
MontMedical · 7/10: Identifies platelet uPA and targeted genetic testing, but ongoing bleeding priorities are less prominent.
Clarity and teaching
OpenEvidence · 8/10: Clear mechanism and useful practical structure, with some overstatement.
MontMedical · 8/10: Organised and focused, although several findings are packed into long sentences.
AI-assisted editorial judgment of these historical texts, published by MontMedical. Read the rubric, anchors and limits. These are answer-quality scores, not measured diagnostic accuracy or patient benefit.
The actual retained wording
OpenEvidence vs MontMedical.
These are verbatim passages from the retained answers, not rewritten examples. Bold, link formatting and line breaks have been removed. Each labelled passage is contiguous; an excerpt may begin within a sentence. Our interpretation and scores are separate.
OpenEvidence
Retained 2026-09-21
Aggregation claim
The isolated, reproducible absence of epinephrine-induced aggregation with otherwise preserved aggregation to ADP, collagen, arachidonic acid, and ristocetin is a recognised, specific laboratory clue to QPD, rather than a nonspecific finding.
Historical label
Reassess the "mild type 1 VWD" label as unsupported given three normal repeat VWF panels with normal multimers; this should be removed from the record to avoid future mismanagement.
MontMedical
Retained 2026-09-21
Leading classification
The patient presents with an autosomal dominant lifelong bleeding diathesis characterized by delayed-onset post-procedural bleeding, mild borderline thrombocytopenia across three generations, and selective absent platelet aggregation to epinephrine, a triad provisionally characteristic of Quebec platelet disorder.
Testing scope
The negative hereditary bleeding gene panel does not exclude Quebec platelet disorder, as it evaluated only coding-region single-nucleotide variants and small indels, whereas Quebec platelet disorder is caused by a 78-kb tandem duplication copy-number variation of the PLAU gene, requiring targeted copy-number or structural variant analysis for molecular confirmation.
The case and the decision
A family has delayed bleeding after procedures, mild thrombocytopenia and absent epinephrine-induced platelet aggregation. Routine plasma clot-lysis testing is normal. An earlier genetic panel covered single-nucleotide changes and small insertions or deletions, with no validated copy-number analysis.
What both explanations do well
Both identify Quebec platelet disorder and explain why a platelet-localised fibrinolytic process can escape routine plasma testing. Primary experiments support that compartment distinction. Both also recognise that the reported panel does not resolve the known PLAU tandem-duplication question. [1] [2]
The wording worth correcting
OpenEvidence calls the isolated epinephrine response a specific laboratory clue rather than a nonspecific finding. Published laboratory descriptions treat aggregation findings as non-diagnostic. It is a useful clue in the family pattern, but not a stand-alone identification of QPD. [3]
MontMedical's provisional classification is better calibrated here. The decisive confirmation is targeted assessment of the relevant structural alteration and phenotype, rather than greater confidence in the aggregation result.
What OpenEvidence gets right—and what neither answer settles
OpenEvidence makes the practical bleeding implications prominent and correctly explains the plasma-versus-platelet problem. This is a narrow wording advantage for MontMedical, not a missed diagnosis by OpenEvidence.
Neither retained answer should be used to conclude that every possible coexisting von Willebrand disorder has been excluded. The case shows that VWF replacement does not adequately explain or control the described episode; that is a different claim.
Retained answer dates: MontMedical 2026-09-21; OpenEvidence 2026-09-21. Excerpt wording was checked against the retained answers; formatting was removed. These versions were selected during development. Complete original run settings and identical submitted prompts are not documented.
This article examines the MontMedical Pro beta using retained diagnostic answers.